Exhibit 99.1 Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights WATERTOWN, Mass., February 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the fourth quarter and full year ended December 3 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-38537 TECTONIC THERAPEUTIC, INC. (Exact name of Registrant as specified in its Charter) Delaware ...

Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. Topline results showed TX45 was well tolerated and improved both left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEFTX2100 advanced into Phase 1a healthy volunteer clinical trial, randomizing the first subject in February 2026, as a potential treatment for Hereditary He ...

Tectonic Therapeutic (NasdaqGM:TECX) Update / briefing February 24, 2026 11:00 AM ET Company ParticipantsAlex Nackenoff - Biotechnology Equity Research AssociateAlise Reicin - President and CEODavid Risinger - Senior Managing DirectorGaurav Maini - VP of Biotech Equity ResearchHanny Al-Samkari - Associate Professor of MedicineMarcie Ruddy - Chief Medical OfficerMartin Auster - Managing DirectorPeter McNamara - Chief Scientific OfficerConference Call ParticipantsBen Burnett - AnalystLeland Gershell - Managin ...

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader bri ...

Core Insights - Tectonic Therapeutic, Inc. is hosting a virtual key opinion leader event to discuss TX2100, a GPCR antagonist aimed at treating Hereditary Hemorrhagic Telangiectasia (HHT) [1][2] Company Overview - Tectonic Therapeutic is a clinical-stage biotechnology company focused on developing therapeutic proteins and antibodies that modulate GPCR activity [9] - The company utilizes its proprietary GEODe™ technology platform to address challenges in GPCR-targeted drug discovery [9][10] Product Development - TX2100 is a potential first-in-class therapeutic candidate targeting a signaling pathway involved in pathological angiogenesis and arteriovenous malformations (AVMs) associated with HHT [3] - The company plans to initiate a Phase 1a clinical trial of TX2100 in healthy volunteers in Q1 2026 [3] Expert Involvement - Dr. Hanny Al-Samkari, an expert in hematology and a key opinion leader, will participate in the event to provide clinical context on HHT and discuss the unmet medical needs in this area [2][5][6] Disease Context - HHT is a rare inherited vascular disorder affecting approximately 75,000 people in the U.S., characterized by fragile blood vessels leading to recurrent bleeding and serious complications [8]

Core Insights - Tectonic Therapeutic, Inc. (NASDAQ:TECX) is recognized as one of the best micro-cap stocks to invest in according to analysts [1] - LifeSci Capital has reiterated a Buy rating on TECX with a price target of $88, indicating strong confidence in the stock's potential [2] Company Overview - Tectonic Therapeutic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCRs) [2][3] - The company has developed the GEODe technology platform to facilitate the discovery and development of GPCR-targeted biologic medicines [3] Product Pipeline - One of the lead product candidates is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, which is the GPCR target of the hormone relaxin [3] - Tectonic is also developing TX2100, aimed at treating hereditary hemorrhagic telangiectasia, and other GPCR modulators for treating fibrosis and related conditions [3]

Summary of Tectonic Therapeutic FY Conference Call Company Overview - **Company**: Tectonic Therapeutic (NasdaqGM: TECX) - **Event**: FY Conference on December 02, 2025 Key Industry Insights - **Focus**: The conference highlighted the significance of the APEX study, which is expected to be pivotal for Tectonic in 2026, marking the beginning of a critical two-year period for the company [1][2] Core Points and Arguments 1. **Enrollment Progress**: - Tectonic met its mid-year recruitment objectives and is on track to meet its end-of-year recruitment goal. As of November, recruitment has shifted to patients with a pulmonary vascular resistance (PVR) greater than three [4][5] - 70% of the total patient population falls within the PVR greater than three category [11][13] 2. **Data Safety Monitoring**: - The last data safety monitoring committee (DSMB) meeting occurred at the end of September, with no safety signals reported. Continuous monitoring is in place [5][6] 3. **Patient Population and Study Design**: - The study is enriched for patients with chronic stable heart failure and high PVR, aiming to improve outcomes in this specific group [30][34] - The primary endpoint focuses on PVR reduction, with a previous phase 1b study showing a 30% decrease in PVR [23][24] 4. **Comparison with Competitors**: - Tectonic's TX45 is differentiated from competitors like AstraZeneca and Lilly based on patient selection and study design. Tectonic's study focuses on a more homogeneous population with specific PVR criteria [30][37] - The mechanism of action for TX45 includes vasodilation and potential antifibrotic effects, which may provide advantages over competitors [39][41] 5. **Future Development Plans**: - Tectonic is considering various options for future studies in heart failure with preserved ejection fraction (HFpEF), including standalone phase 2 or phase 2/3 studies [29][30] - The company plans to start a healthy volunteer study for TX2100 in early 2026, focusing on pharmacokinetics and safety [47] Other Important Information - **Financial Position**: Tectonic reported approximately $268 million in cash, providing a runway into the fourth quarter of 2028 [49] - **Market Context**: The discussion emphasized the complexity of the heart failure market, with multiple mechanisms and treatment options available, indicating a significant opportunity for Tectonic's therapies [43][44]

Core Insights - Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company focused on developing therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs) [4] Upcoming Conferences - Tectonic management will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 3:30 PM EST in New York, NY, in a fireside chat format [2] - The company will also attend the Evercore 8th Annual Healthcare Conference on December 3, 2025, in Miami, FL, conducting investor meetings [2][3] Company Overview - Tectonic utilizes its proprietary GEODe™ technology platform to enhance GPCR-targeted drug discovery, aiming to develop biologic medicines for areas with significant unmet medical needs [4] - The company is headquartered in Watertown, Massachusetts, and focuses on improving patient quality of life through innovative therapeutic options [4]

Group 1 - The article discusses Tectonic Therapeutic, Inc. (TECX) and its potential expansion of the TX45 candidate following positive interim data [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Tectonic Therapeutic, Inc. or the biotech industry [1][3][4]